345 related articles for article (PubMed ID: 35145911)
1. (Im)maturity in Tumor Ecosystem.
Mortezaee K; Majidpoor J
Front Oncol; 2021; 11():813897. PubMed ID: 35145911
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
Weber R; Fleming V; Hu X; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():1310. PubMed ID: 29942309
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
4. Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies.
Mortezaee K; Majidpoor J; Najafi S; Tasa D
Biomed Pharmacother; 2023 Feb; 158():114150. PubMed ID: 36577330
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
[TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
Mortezaee K; Majidpoor J
Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
[TBL] [Abstract][Full Text] [Related]
8. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
9. Immune evasion by cancer stem cells.
Tsuchiya H; Shiota G
Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
[TBL] [Abstract][Full Text] [Related]
10. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
11. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.
Ostrand-Rosenberg S; Horn LA; Ciavattone NG
Front Oncol; 2019; 9():215. PubMed ID: 31001479
[TBL] [Abstract][Full Text] [Related]
13. Expression of checkpoint molecules on myeloid-derived suppressor cells.
Ballbach M; Dannert A; Singh A; Siegmund DM; Handgretinger R; Piali L; Rieber N; Hartl D
Immunol Lett; 2017 Dec; 192():1-6. PubMed ID: 28987474
[TBL] [Abstract][Full Text] [Related]
14. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
15. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy.
Bai R; Cui J
Front Immunol; 2022; 13():886931. PubMed ID: 35634343
[TBL] [Abstract][Full Text] [Related]
16. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
17. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
18. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
19. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
Bruno A; Mortara L; Baci D; Noonan DM; Albini A
Front Immunol; 2019; 10():771. PubMed ID: 31057536
[TBL] [Abstract][Full Text] [Related]
20. Modified method for differentiation of myeloid-derived suppressor cells
Zhou H; Xie Z; Morikawa N; Sakurai F; Mizuguchi H; Okuzaki D; Okada N; Tachibana M
Biochem Biophys Rep; 2023 Mar; 33():101416. PubMed ID: 36605123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
